Premium
Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D 3 analogue shows relation to promoter selectivity
Author(s) -
Danielsson Carina,
Mathiasen Ida S.,
James Sharon Y.,
Nayeri Sepideh,
Bretting Claus,
Hansen Christina Mørk,
Colston Kay W.,
Carlberg Carsten
Publication year - 1997
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/(sici)1097-4644(19970915)66:4<552::aid-jcb14>3.0.co;2-d
Subject(s) - calcitriol receptor , transcription factor , retinoid x receptor , retinoid , nuclear receptor , apoptosis , calcitriol , transcription (linguistics) , chemistry , receptor , biology , microbiology and biotechnology , biochemistry , gene , endocrinology , retinoic acid , vitamin d and neurology , linguistics , philosophy
Abstract The biologically active form of vitamin D 3 , the nuclear hormone 1α,25‐dihydroxyvitamin D 3 (VD), is an important regulator of cellular growth, differentiation, and death. The hormone mediates its action through the activation of the transcription factor VDR, which is a member of the superfamily of nuclear receptors. In most cases the ligand‐activated VDR is found in complex with the retinoid X receptor (RXR) and stimulates gene transcription mainly from VD response elements (VDREs) that are formed by two hexameric core binding motifs and are arranged either as a direct repeat spaced by three nucleotides (DR3) or as an inverted palindrome spaced by nine nucleotides (IP9). The two VD analogues CB1093 and EB1089 are both very potent inhibitors of the proliferation of MCF‐7 cultured breast cancer cells displaying approximately 100‐fold lower IC 50 values (0.1 nM) than the natural hormone. In addition, CB1093 is even more potent in vivo than EB1089 in producing regression of experimental mammary tumors. Moreover, both VD analogues induce apoptosis in MCF‐7 cells, but CB1093 is effective at concentrations approximately 10‐fold lower than EB1089. In accordance, the reduction of Bcl‐2 protein expression showed CB1093 to be more potent than EB1089. This suggests that the antiproliferative effect of CB1093 may be related mainly to its apoptosis inducing effect, whereas EB1089 may preferentially have effects on growth arrest. EB1089 is known to result in a selectivity for the activation of IP9‐type VDREs, whereas CB1093 shows a preference for the activation of DR3‐type VDREs. This promoter selectivity suggests that the effects of VD and its analogues on growth arrest and the induction of apoptosis may be mediated by different primary VD responding genes. In conclusion, CB1093 was found to be a potent inhibitor of rat mammary tumor growth in vivo. CB1093 also displayed a high potency in vitro in the induction of apoptosis, a process that may be linked to a promoter selectivity for DR3‐type VDREs. J. Cell. Biochem. 66: 552–562, 1997. © 1997 Wiley‐Liss, Inc.